The treatment being tested is atezolizumab, which is given as an infusion, meaning it is administered directly into the bloodstream through a vein. This study will also include a comparison with a placebo, which is a substance with no active medication, to see how effective atezolizumab is on its own. The study will last for up to 12 months, during which participants will receive the treatment and have regular check-ups to monitor their health and the status of their cancer.

Participants in the study will be closely monitored for any side effects or changes in their condition. The study aims to provide valuable information on whether atezolizumab can be a beneficial treatment option for patients with this specific type of colorectal cancer who are not suitable for standard chemotherapy. The results could potentially lead to new treatment options for these patients in the future.

Participants in the study will receive either the standard chemotherapy treatment or the combination of chemotherapy and atezolizumab. The treatment will be administered through an intravenous infusion, which means the medication is given directly into a vein. The study will continue for a period of time to monitor the effects of the treatment on the participants’ health and to see if the cancer returns. The study aims to provide valuable information on whether the addition of atezolizumab can offer better outcomes for patients with this type of colon cancer.

Throughout the study, participants will be closely monitored by healthcare professionals to ensure their safety and to track the progress of their treatment. The study will help researchers understand if the combination of atezolizumab with standard chemotherapy can be a more effective treatment option for patients with stage III colon cancer and deficient DNA mismatch repair. This research could potentially lead to improved treatment strategies for this specific group of patients.

The purpose of the study is to evaluate how effective the combination of Temozolomide and Irinotecan is in treating patients with this specific type of colorectal cancer. Participants in the study will receive these medications after they have completed standard chemotherapy, which usually includes a drug called oxaliplatin. The study will monitor patients to see if the cancer remains undetectable in their blood tests, which is a sign that the treatment might be working. Some patients will receive a placebo instead of the active medications to compare the results.

Throughout the study, patients will be regularly checked to ensure their safety and to monitor any side effects from the treatment. The study will also look at how long patients remain free of cancer and their overall survival. Additionally, researchers will collect information from patients about their quality of life during the study. This information will help determine if the treatment is not only effective but also tolerable for patients. The study aims to provide valuable insights into whether this combination of medications can be a beneficial treatment option for patients with this type of colorectal cancer.

The purpose of the study is to evaluate how effective dostarlimab is when used before and after surgery, compared to the usual care. Participants will receive either dostarlimab or the standard treatment, which may include medications like fluorouracil, capecitabine, folinic acid, and oxaliplatin. These medications are commonly used in cancer treatment and work by interfering with the growth of cancer cells. The study will last for a period of up to 12 months, during which participants will be closely monitored by healthcare professionals.

Throughout the study, participants will undergo regular assessments to check the progress of their treatment. This includes monitoring for any side effects and evaluating the response of the cancer to the treatment. The study aims to provide valuable information on whether dostarlimab can improve outcomes for patients with this specific type of colon cancer. Participants will receive care and support from the study team throughout the trial period.

The medications involved in this study include capecitabine, fluorouracil, and calcium folinate, which are types of chemotherapy drugs. Additionally, the study uses bevacizumab, panitumumab, and cetuximab, which are monoclonal antibodies. Monoclonal antibodies are proteins designed to target specific parts of cancer cells. The study is divided into two groups, or cohorts. One group will receive maintenance therapy with fluoropyrimidine and anti-EGFR (epidermal growth factor receptor) drugs, while the other group will receive fluoropyrimidine and anti-VEGF (vascular endothelial growth factor) drugs.

The purpose of the study is to assess how effective this treatment approach is in preventing the cancer from progressing over a period of several months. Participants will undergo the initial Holmium-166 TARE procedure, followed by regular administration of the maintenance therapy drugs. The study will monitor the participants’ health and the progression of their cancer over time to gather data on the treatment’s effectiveness and safety. Some participants may receive a placebo as part of the study design. The study is expected to continue until 2026.

Participants in the study will receive the chemotherapy treatment for six weeks, which is divided into three courses. After completing the chemotherapy, they will undergo surgery to remove the cancer. The study will monitor the participants over a period of time to see how well they respond to the treatment and to check if they remain free of cancer. The trial will also assess the safety of the treatment and any side effects that may occur.

The study will evaluate various aspects of the participants’ health, including their quality of life and overall survival rates. It will also look at how the cancer responds to the treatment and whether the chemotherapy helps in reducing the size or spread of the cancer before surgery. The goal is to provide valuable information that could help improve treatment strategies for elderly patients with colon cancer.

The purpose of this study is to evaluate how well these treatments work in preventing the return of cancer in patients who have already undergone treatment and currently have no detectable disease. Participants will be randomly assigned to receive either the combination of durvalumab and regorafenib or no additional treatment. The study will last for up to 12 months, during which time the health of the participants will be closely monitored.

The main goal is to determine if the combination of these medications can help patients remain free of cancer for a longer period. The study will also look at the overall survival of participants, any side effects they may experience, and how well they adhere to the treatment plan. This research aims to provide valuable insights into improving outcomes for patients with advanced colorectal cancer.